Litigation Details for UCB Inc. v. Accord Healthcare Inc. (D. Del. 2013)

UCB Inc. v. Accord Healthcare Inc. (D. Del. 2013)

Docket	1:13-cv-01206	Date Filed	2013-07-10
Court	District Court, D. Delaware	Date Terminated	2016-09-02
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	MYLAN PHARMACEUTICALS INC.
Patents	RE38,551
Attorneys	George F. Pappas
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for UCB Inc. v. Accord Healthcare Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-07-10				External link to document

Litigation summary and analysis for: UCB Inc. v. Accord Healthcare Inc. (D. Del. 2013)

Last updated: May 15, 2026

UCB Inc. v. Accord Healthcare Inc. (1:13-cv-01206): Litigation Summary, Claims at Issue, and Patent-Expiry Impact on Generic Entry

UCB Inc.’s federal infringement case against Accord Healthcare Inc., docketed as 1:13-cv-01206, is aimed at blocking Accord’s proposed generic entry for a UCB product using U.S. patent rights listed in FDA Orange Book(s). The litigation posture and downstream generic entry risk turns on (1) which U.S. patents UCB asserted in the complaint, (2) whether Accord triggered a Paragraph IV certification for those patents, and (3) the timing of any final judgments, stays, and settlement-driven market commitments.

This matter is one of the U.S. Hatch-Waxman IP disputes where the actionable question is not abstract patent validity. It is whether Accord’s ANDA design-around or non-infringement theories narrowed the asserted claims and how the court’s rulings affected U.S. exclusivity and launch scheduling.

---

What patents were asserted in UCB Inc. v. Accord Healthcare Inc. (1:13-cv-01206)?

Featured-snippet answer: The litigation record’s value for launch and licensing is the specific U.S. patent numbers asserted by UCB and the asserted claim sets (drug substance, formulation, method-of-use, and/or packaging).

Under the Hatch-Waxman framework, the infringement complaint typically ties to patents listed for the referenced drug in the Orange Book and to the ANDA’s paragraph certifications for those listed patents. The legal analysis in this case is therefore structured around:

Which patent families usually drive these disputes

• Active ingredient (API) composition of matter patents (stronger coverage, harder to design around).
• Formulation patents (often challenged via different excipient systems or processing parameters).
• Method-of-use patents (often challenged through different clinical dosing regimens or label carve-outs).
• Manufacturing method patents (often contested on process differences and infringement proof).

What court claim construction means commercially

If the case turns on Markman claim construction, the outcome usually determines:

• whether Accord’s ANDA product falls inside the claim scope;
• whether UCB’s patents survive validity challenges; and
• what “work” the generic must do (label changes, formulation changes, additional development) to mitigate injunction risk.

---

Was Accord’s ANDA a Paragraph IV challenge, and how did that control litigation timing?

Featured-snippet answer: In ANDA litigation of this type, Accord’s ANDA is assessed by whether it included Paragraph IV certifications to the patents asserted by UCB. That certification usually dictates:

• the start of statutory litigation;
• the timing of FDA marketing-event eligibility;
• whether a 30-month stay applied; and
• the practical launch window even without an immediate final judgment.

How Paragraph IV timing converts into launch calendars

The commercial impact is driven by the interaction between:

• the ANDA filing date and Paragraph IV certification,
• the date UCB filed suit (triggering statutory stay mechanisms),
• and whether there is a final injunction or a settlement that lifts/extends stay periods.

Even where patents later expire naturally, the launch can remain blocked during the stay or under settlement terms.

---

What was the procedural timeline in 1:13-cv-01206 and what were the key litigation milestones?

Featured-snippet answer: The procedural milestones that matter for investors and licensing teams are:

1. complaint filing date,
2. service and answer,
3. claim construction (Markman) date,
4. summary judgment or dispositive rulings,
5. trial dates (or stipulations),
6. final judgment date,
7. appeal posture if any.

Why timeline beats “outcome summary” for generic planning

For ANDA disputes, a final merits ruling is often less useful than:

• whether the case produced an injunction or stipulated final judgment;
• whether there is a consent decree or settlement that defines entry dates;
• whether court decisions shortened or lengthened exclusivity.

Status signals that affect market risk

• Early stay motions: can delay discovery and final claim interpretation.
• Dispositive motion grants: can narrow the case to one or two patents or invalidate key claims.
• Partial settlement: can lift some patent barriers while keeping others intact.

---

How did the court rule on infringement and validity in UCB v. Accord?

Featured-snippet answer: The business question is whether UCB obtained a ruling that is binding in the U.S. market. That typically manifests as:

• infringement findings (or non-infringement),
• validity findings (or invalidation),
• and any injunction or “carve-out” remedy.

What infringement theory usually looks like

• Direct infringement based on the accused ANDA product.
• Induced or contributory infringement if UCB argued downstream conduct.

What validity challenges usually focus on

• Written description and enablement.
• Obviousness over prior art.
• Anticipation (novelty).
• Indefiniteness.

What matters for generic entry after an infringement ruling

If the asserted claims are found infringed and valid:

• generic entry is blocked absent design-around or settlement. If claims are invalidated or not infringed:
• launch risk drops rapidly once regulatory approvals are in place.

---

Did UCB obtain an injunction or settlement terms that affected Accord’s launch date?

Featured-snippet answer: Litigation outcomes in this category often resolve via a settlement agreement that sets a launch date, payment terms, or conditional triggers (for example, earlier launch if regulatory approvals occur by a defined date).

Settlement terms that control exclusivity exposure

Common settlement constructs include:

• agreed “effective launch date” for the generic;
• stipulations of non-infringement or dismissal of certain patents;
• covenants not to sue for specific remaining patents;
• mutual releases with defined carve-outs.

Why settlements create clearer risk than court outcomes

Courts can decide validity while leaving other patents in play. Settlements often define a date-based barrier that is more useful for commercialization planning.

---

What is the Orange Book status of the UCB drug(s) tied to 1:13-cv-01206?

Featured-snippet answer: The Orange Book status for the referenced product defines the patent stack and the certification profile (Paragraph II, III, IV).

Orange Book listings determine:

• which patents must be addressed in ANDA litigation;
• which patent expiration is the “hardest” barrier;
• and whether any patents are “listed” after initial approval in ways that expand the litigation surface.

How to map Orange Book patents to asserted litigation

A credible litigation analysis maps:

• asserted Orange Book patents to the NDA/ANDA product reference label,
• to the accused product formulation and indication scope,
• to the label changes that may avoid method-of-use infringement.

---

When does the asserted patent estate expire, and how does that align with generic entry risk?

Featured-snippet answer: The key is whether the asserted patents are:

• composition of matter (usually longest tail),
• formulation (may be later tail but narrower scope),
• or method-of-use (often label-driven and can be avoided by label design).

Patent-expiry mechanics that decide launch

For Hatch-Waxman disputes:

• Natural patent expiration can allow launch after regulatory readiness.
• Any statutory stays delay launch even if patents later expire.
• Settlement terms can preempt early launch even when court decisions do not fully resolve every asserted right.

---

How strong is UCB’s patent estate versus Accord’s infringement defenses in this case?

Featured-snippet answer: Strength in these cases typically correlates to:

• breadth of the asserted claims,
• closeness of the ANDA formulation or method to the asserted embodiments,
• and whether prior art attacks the claims with high probability of invalidity.

Common generic defenses that can neutralize risk

• Non-infringement by design-around (different excipient or dose form).
• Claim construction narrowing (making the accused product fall outside scope).
• Invalidity (obviousness, anticipation).

What “strength” means for licensing

For licensing and clearance:

• the decisive factor is whether remaining asserted claims after the dispositive phase still cover Accord’s intended product.

---

Which competing generics or biosimilars are structurally exposed to this litigation logic?

Featured-snippet answer: The litigation framework affects competitors seeking ANDA approval for the same referenced drug by:

• defining the patent stack U.S. regulators and courts treat as barriers; and
• shaping the timing and strategy of other Paragraph IV filers.

Market spillover effects

Even competitors not party to the case face:

• potential estoppel effects,
• similar label design-around constraints,
• and practical launch timing set by the same Orange Book patent expiry and any negotiated settlement patterns.

---

What manufacturing/IP barriers could block Accord or other ANDA filers despite patent expiration?

Featured-snippet answer: Even if patents expire or are ruled invalid, generic launch can still face barriers from:

• facility readiness and CMC validation,
• stability and bioequivalence constraints,
• and any remaining patent or regulatory exclusivity.

CMC and patent scope overlap

Where formulation patents exist, the generic must meet:

• the claimed formulation characteristics (if still asserted),
• or demonstrate non-infringement via differences that also satisfy FDA quality requirements.

---

Key Takeaways

• UCB Inc. v. Accord Healthcare Inc. (1:13-cv-01206) is a Hatch-Waxman-style infringement dispute where the practical value lies in the specific Orange Book patent stack tied to the asserted claims and the Paragraph IV certification posture.
• Litigation leverage and generic launch risk depend on: which patents UCB asserted, whether a 30-month stay applied, the court’s claim construction and dispositive rulings, and whether settlement terms created an agreed entry date.
• For commercial planning, the decisive deliverable is the mapping of asserted patents to Orange Book listings and expiration dates, then aligning those with any settlement or injunction-based launch triggers.

---

FAQs

1) What is the fastest way to determine the launch-blocking patents in UCB v. Accord (1:13-cv-01206)?
Identify the asserted U.S. patent numbers in the complaint and match them to the Orange Book for the referenced NDA/label; then check which patents are tied to Paragraph IV certifications.

2) Does a partial settlement in a U.S. patent infringement case still affect FDA launch timing?
Yes. Settlement terms can create a date-based marketing commitment independent of later patent outcomes, restricting entry even if some barriers are resolved.

3) How does label design affect method-of-use infringement risk in ANDA litigation?
Method-of-use patents can be avoided by carving out the infringing indication or dosing instruction, depending on claim scope and what the generic’s proposed labeling covers.

4) If patents are invalidated, can a generic still face delays?
Yes. Regulatory readiness, CMC approvals, and any remaining patents or statutory exclusivities can still block launch.

5) Do other ANDA filers get impacted by litigation not involving them?
Yes. Patent rulings and settlement-driven entry windows influence market strategy for other Paragraph IV filers targeting the same referenced product.

---

References (APA)

1. U.S. District Court for the District of New Jersey. UCB Inc. v. Accord Healthcare Inc., No. 1:13-cv-01206.